CD274 and neoplasm: For example, combining PD-1/PD-L1 antibodies with regorafenib: in the REGOMUNE study, combining regorafenib with avelumab for the treatment of MSS CRC patients demonstrated that this combination therapy can enhance anti-tumor immunity; in the REGOTORI study, the combination of regorafenib with toripalimab for the treatment of MSS mCRC showed efficacy but did not reach statistical significance.